Retraction to Platelets and their role in cancer evolution and immune system [Transl Lung Cancer Res. 4, (2015), 713-720] 10.3978/j.issn.2218-6751.2015.10.09;Platelets and their role in cancer evolution and immune system

Translational Lung Cancer Research

Volumn 4, Issue 6, 2015, Pages 713-720

  Karachaliou, Niki ^a   Pilotto, Sara ^b   Bria, Emilio ^b   Rosell, Rafael ^a,c,d,e,f  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c Pangaea Biotech   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e Molecular Oncology Research (MORe) Foundation   (Spain)

^f Germans Trias i Pujol Research Institute in Health Sciences   (Spain)

Author keywords

Cancer; Hemostasis; Immune system; Metastasis; Platelets; Tumor cell induced platelet aggregation (TCIPA)

Indexed keywords

CARCINOGENESIS; CELL FUNCTION; CELL PROLIFERATION; HEMOSTASIS; HUMAN; IMMUNE SYSTEM; METASTASIS; NONHUMAN; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOSIS; TUMOR MICROENVIRONMENT;

EID: 84960081792     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.21037/tlcr.2016.04.06     Document Type: Erratum

References (57)

1. Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science 2010;328:562-4.
2. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer 2011;11:123-34.
3. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011;9:237-49.
4. Reed GL, Fitzgerald ML, Polgár J. Molecular mechanisms of platelet exocytosis: insights into the "secrete" life of thrombocytes. Blood 2000;96:3334-42.
5. Ma YQ, Qin J, Plow EF. Platelet integrin alpha(IIb) beta(3): activation mechanisms. J Thromb Haemost 2007;5:1345-52.
6. Broos K, Feys HB, De Meyer SF, et al. Platelets at work in primary hemostasis. Blood Rev 2011;25:155-67.
7. Jackson SP. Arterial thrombosis--insidious, unpredictable and deadly. Nat Med 2011;17:1423-36.
8. McKenzie SE, Taylor SM, Malladi P, et al. The role of the human Fc receptor Fc gamma RIIA in the immune clearance of platelets: a transgenic mouse model. J Immunol 1999;162:4311-8.
9. Stolla M, Stefanini L, André P, et al. CalDAG-GEFI deficiency protects mice in a novel model of Fcgamma RIIA-mediated thrombosis and thrombocytopenia. Blood 2011;118:1113-20.
10. Urbanus RT, van der Wal DE, Koekman CA, et al. Patient autoantibodies induce platelet destruction signals via raftassociated glycoprotein Ibalpha and Fc RIIa in immune thrombocytopenia. Haematologica 2013;98:e70-2.
11. Warkentin TE, Greinacher A, Gruel Y, et al. Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011;9:2498-500.
12. Tilley DO, Arman M, Smolenski A, et al. Glycoprotein Ibalpha and FcgammaRIIa play key roles in platelet activation by the colonizing bacterium, Streptococcus oralis. J Thromb Haemost 2013;11:941-50.
13. Arman M, Krauel K, Tilley DO, et al. Amplification of bacteria-induced platelet activation is triggered by FcgammaRIIA, integrin alphaIIbbeta3, and platelet factor 4. Blood 2014;123:3166-74.
14. Mitrugno A, Williams D, Kerrigan SW, et al. A novel and essential role for FcgammaRIIa in cancer cell-induced platelet activation. Blood 2014;123:249-60.
15. Neves SR, Ram PT, Iyengar R. G protein pathways. Science 2002;296:1636-9.
16. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ Res 2006;99:1293-304.
17. Jackson SP, Nesbitt WS, Kulkarni S. Signaling events underlying thrombus formation. J Thromb Haemost 2003;1:1602-12.
18. Brass LF, Zhu L, Stalker TJ. Novel therapeutic targets at the platelet vascular interface. Arterioscler Thromb Vasc Biol 2008;28:s43-50.
19. Vandendries ER, Furie BC, Furie B. Role of P-selectin and PSGL-1 in coagulation and thrombosis. Thromb Haemost 2004;92:459-66.
20. Gitz E, Pollitt AY, Gitz-Francois JJ, et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 2014;124:2262-70.
21. Hou TZ, Bystrom J, Sherlock JP, et al. A distinct subset of podoplanin (gp38) expressing F4/80+ macrophages mediate phagocytosis and are induced following zymosan peritonitis. FEBS Lett 2010;584:3955-61.
22. Kerrigan AM, Navarro-Nuñez L, Pyz E, et al. Podoplaninexpressing inflammatory macrophages activate murine platelets via CLEC-2. J Thromb Haemost 2012;10:484-6.
23. Peters A, Pitcher LA, Sullivan JM, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 2011;35:986-96.
24. Miyamoto Y, Uga H, Tanaka S, et al. Podoplanin is an inflammatory protein upregulated in Th17 cells in SKG arthritic joints. Mol Immunol 2013;54:199-207.
25. May F, Hagedorn I, Pleines I, et al. CLEC-2 is an essential platelet-activating receptor in hemostasis and thrombosis. Blood 2009;114:3464-72.
26. Suzuki-Inoue K. Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation. J Biochem 2011;150:127-32.
27. Bender M, May F, Lorenz V, et al. Combined in vivo depletion of glycoprotein VI and C-type lectin-like receptor 2 severely compromises hemostasis and abrogates arterial thrombosis in mice. Arterioscler Thromb Vasc Biol 2013;33:926-34.
28. Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res 2012;129 Suppl 1:S30-7.
29. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 1968;61:46-52.
30. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med 1981;95:636-41.
31. Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010;115:3427-36.
32. Bastida E, Almirall L, Ordinas A. Tumor-cell-induced platelet aggregation is a glycoprotein-dependent and lipoxygenase-associated process. Int J Cancer 1987;39:760-3.
33. Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999;59:1295-300.
34. Wahrenbrock M, Borsig L, Le D, et al. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas. J Clin Invest 2003;112:853-62.
35. Barrientos S, Stojadinovic O, Golinko MS, et al. Growth factors and cytokines in wound healing. Wound Repair Regen 2008;16:585-601.
36. Kuznetsov HS, Marsh T, Markens BA, et al. Identification of luminal breast cancers that establish a tumorsupportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2012;2:1150-65.
37. Nilsson RJ, Balaj L, Hulleman E, et al. Blood platelets contain tumor-derived RNA biomarkers. Blood 2011;118:3680-3.
38. Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelialmesenchymal- like transition and promotes metastasis. Cancer Cell 2011;20:576-90.
39. Schumacher D, Strilic B, Sivaraj KK, et al. Plateletderived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013;24:130-7.
40. Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proc Natl Acad Sci U S A 2014;111:E3053-61.
41. Takagi S, Sato S, Oh-hara T, et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One 2013;8:e73609.
42. Goubran HA, Stakiw J, Radosevic M, et al. Platelets effects on tumor growth. Semin Oncol 2014;41:359-69.
43. Yoshida T, Ishii G, Goto K, et al. Podoplaninpositive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res 2015;21:642-51.
44. Kitamura T, Qian BZ, Pollard JW. Immune cell promotion of metastasis. Nat Rev Immunol 2015;15:73-86.
45. Camerer E, Qazi AA, Duong DN, et al. Platelets, proteaseactivated receptors, and fibrinogen in hematogenous metastasis. Blood 2004;104:397-401.
46. Karpatkin S, Pearlstein E, Ambrogio C, et al. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988;81:1012-9.
47. Gil-Bernabé AM, Ferjancic S, Tlalka M, et al. Recruitment of monocytes/macrophages by tissue factor-mediated coagulation is essential for metastatic cell survival and premetastatic niche establishment in mice. Blood 2012;119:3164-75.
48. Qian BZ, Li J, Zhang H, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
49. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009;9:239-52.
50. Palumbo JS, Talmage KE, Massari JV, et al. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 2005;105:178-85.
51. Palumbo JS, Talmage KE, Massari JV, et al. Tumor cellassociated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and-independent mechanisms. Blood 2007;110:133-41.
52. Sambrano GR, Weiss EJ, Zheng YW, et al. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001;413:74-8.
53. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood 2000;96:3302-9.
54. Versteeg HH, Schaffner F, Kerver M, et al. Proteaseactivated receptor (PAR) 2, but not PAR1, signaling promotes the development of mammary adenocarcinoma in polyoma middle T mice. Cancer Res 2008;68:7219-27.
55. Hu L, Roth JM, Brooks P, et al. Twist is required for thrombin-induced tumor angiogenesis and growth. Cancer Res 2008;68:4296-302.
56. Palumbo JS, Degen JL. Mechanisms linking tumor cellassociated procoagulant function to tumor metastasis. Thromb Res 2007;120 Suppl 2:S22-8.
57. Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009;69:7775-83.